The temporal requirement of RA for pectoral fin field induction
| A Inhibition of pectoral fin development | ||||
| Beginning of antagonist treatment* | Sample size (n) | Antagonist (concentration) | Number of embryos lacking tb×5a expression in pectoral fins (%of sample) | Loss of tb×5a expression |
| 5.3 hpf | 60 | BMS (10−5 M) | 60 (100%) | + |
| 39 | BMS (5×10−6 M) | 39 (100%) | + | |
| 8 hpf | 64 | BMS (10−5 M) | 64 (100%) | + |
| 41 | BMS (5×10−6 M) | 41 (100%) | + | |
| 10 hpf | 102 | BMS (10−5 M) | 102 (100%) | + |
| 41 | BMS (5×10−6 M) | 41 (100%) | + | |
| 30 | DEAB (10−5 M) | 30 (100%) | + | |
| 11 hpf (3 s) | 40 | BMS (10−5 M) | 40 (100%) | + |
| 30 | DEAB (10−5 M) | 30 (100%) | ||
| 12 hpf (6 s) | 40 | BMS (10−5 M) | 40 (100%) | + |
| 30 | DEAB (10−5 M) | 26 (87%) | ||
| 13 hpf (8 s) | 40 | BMS (10−5 M) | 18 (45%) | +/− |
| 30 | DEAB (10−5 M) | 0 (0%) | ||
| 14 hpf (10 s) | 40 | BMS (10−5 M) | 0 (0%) | − |
| 30 | DEAB (10−5 M) | 0 (0%) | ||
| 14.5 hpf (11 s) | 40 | BMS (10−5 M) | 0 (0%) | − |
| 15.5 hpf (13 s) | 40 | BMS (10−5 M) | 0 (0%) | − |
| B Rescue of pectoral fin development | ||||
| Beginning of RA treatment | Sample size (n) | Number of n/smutants†(expected number of n/s mutants) | Number of n/s mutants expressing tb×5a in pectoral fins (% of rescued n/s mutants) | Rescue of tb×5a expression in n/s |
| DMSO control 5.3 hpf | 51 | 6 (13) | 6 (100%) | − |
| 5.3 hpf | 55 | Not detectable (18) | Not detectable (100%) | + |
| 8 hpf | 80 | Not detectable (20) | Not detectable (100%) | + |
| 9 hpf | 80 | Not detectable (20) | Not detectable (100%) | + |
| 10 hpf | 33 | 6 (8) | 6 (100%) | + |
| 11 hpf (3s) | 49 | 9 (12) | 9 (100%) | + |
| 12 hpf (6s) | 117 | 35 (29) | 33 (94%) | + |
| 13 hpf (8s) | 134 | 36 (33,5) | 0 (0%) | − |
| 16 hpf (14s) | 43 | 10 (11) | 0 (0%) | − |
| 19 hpf (20s) | 50 | 10 (12,5) | 0 (0%) | − |
| 22 hpf (26s) | 38 | 12 (9,5) | 0 (0%) | − |
| A Inhibition of pectoral fin development | ||||
| Beginning of antagonist treatment* | Sample size (n) | Antagonist (concentration) | Number of embryos lacking tb×5a expression in pectoral fins (%of sample) | Loss of tb×5a expression |
| 5.3 hpf | 60 | BMS (10−5 M) | 60 (100%) | + |
| 39 | BMS (5×10−6 M) | 39 (100%) | + | |
| 8 hpf | 64 | BMS (10−5 M) | 64 (100%) | + |
| 41 | BMS (5×10−6 M) | 41 (100%) | + | |
| 10 hpf | 102 | BMS (10−5 M) | 102 (100%) | + |
| 41 | BMS (5×10−6 M) | 41 (100%) | + | |
| 30 | DEAB (10−5 M) | 30 (100%) | + | |
| 11 hpf (3 s) | 40 | BMS (10−5 M) | 40 (100%) | + |
| 30 | DEAB (10−5 M) | 30 (100%) | ||
| 12 hpf (6 s) | 40 | BMS (10−5 M) | 40 (100%) | + |
| 30 | DEAB (10−5 M) | 26 (87%) | ||
| 13 hpf (8 s) | 40 | BMS (10−5 M) | 18 (45%) | +/− |
| 30 | DEAB (10−5 M) | 0 (0%) | ||
| 14 hpf (10 s) | 40 | BMS (10−5 M) | 0 (0%) | − |
| 30 | DEAB (10−5 M) | 0 (0%) | ||
| 14.5 hpf (11 s) | 40 | BMS (10−5 M) | 0 (0%) | − |
| 15.5 hpf (13 s) | 40 | BMS (10−5 M) | 0 (0%) | − |
| B Rescue of pectoral fin development | ||||
| Beginning of RA treatment | Sample size (n) | Number of n/smutants†(expected number of n/s mutants) | Number of n/s mutants expressing tb×5a in pectoral fins (% of rescued n/s mutants) | Rescue of tb×5a expression in n/s |
| DMSO control 5.3 hpf | 51 | 6 (13) | 6 (100%) | − |
| 5.3 hpf | 55 | Not detectable (18) | Not detectable (100%) | + |
| 8 hpf | 80 | Not detectable (20) | Not detectable (100%) | + |
| 9 hpf | 80 | Not detectable (20) | Not detectable (100%) | + |
| 10 hpf | 33 | 6 (8) | 6 (100%) | + |
| 11 hpf (3s) | 49 | 9 (12) | 9 (100%) | + |
| 12 hpf (6s) | 117 | 35 (29) | 33 (94%) | + |
| 13 hpf (8s) | 134 | 36 (33,5) | 0 (0%) | − |
| 16 hpf (14s) | 43 | 10 (11) | 0 (0%) | − |
| 19 hpf (20s) | 50 | 10 (12,5) | 0 (0%) | − |
| 22 hpf (26s) | 38 | 12 (9,5) | 0 (0%) | − |